Why CSL’s US$11.7bn Bet On Vifor Has Failed, And If There Is Hope For The Future?

It is hard to look back on something and say it failed especially if it was a US$11.7bn bet as CSL’s Vifor acquisition was. But what else can you say? Impairments now total roughly US$6.5bn, the share price is barely over $100 having peaked at over $300 only a couple of years ago and the company is still without a permanent CEO. The question for investors is whether this moment represents a reset or a structural break. There’s so much that can be said about everything that has gone wrong with CSL – probably the most clickbaity would be its vaccines business which has been hit by anti-vaxxer sentiment in the US. But this article will focus on Vifor.

Why CSL Bought Vifor

Putting the price paid to the side, we think the logic behind the Vifor acquisition was coherent on paper. CSL’s plasma business, while dominant, had been exposed during COVID‑19 when lockdowns curtailed plasma donations and constrained supply. Management was understandably motivated to reduce concentration risk and build a third growth pillar.

Vifor appeared to offer that opportunity. The company held leading positions in iron deficiency, nephrology and cardio‑renal therapies, with a portfolio centred on Ferinject/Injectafer, Venofer, Veltassa and the newly launched Korsuva. Analysts at Jefferies drew a direct parallel to CSL Behring, noting that Vifor’s market structure, regulatory barriers and limited competition resembled CSL’s existing plasma franchise.

Then‑CEO Paul Perreault framed the deal as a direct expression of CSL’s 2030 strategy: adding a high‑growth, cash‑generative business that would expand CSL’s presence in the rapidly growing nephrology market. The combined pipeline was expected to grow by 37%, with up to four launches in FY22/23. In strategic terms, it was difficult to fault the ambition.

Why CSL Paid So Much

At US$179.25 per share, CSL’s offer represented a premium of roughly 60% to Vifor’s early‑December 2021 closing price, overtaking Merck’s US$11.5bn Acceleron deal as the largest biopharma transaction of that year. Patinex AG, Vifor’s largest shareholder with a 23% stake, agreed to tender its shares, suggesting the price was attractive to those closest to the business.

Three forces likely explain the premium. First, the deal was struck in the final months of a bull market defined by elevated M&A multiples and cheap debt. Second, CSL viewed Vifor’s iron franchise, particularly its intravenous iron therapies, as defensible given limited competition. Third, and perhaps most importantly, there was competitive tension.

The Australian Financial Review had previously reported CSL was exploring a deal around US$7.1bn, implying a bidding dynamic that pushed the final price materially higher. In hindsight, the 60% premium left almost no margin for execution risk.

What Went Wrong

The problems at CSL Vifor emerged gradually, then all at once.

The first signs appeared in 2024, when then‑CEO Paul McKenzie warned that parts of the Vifor portfolio were facing “commercial and regulatory headwinds.” Ferinject, the division’s top product, encountered step‑edit pressure in key markets, with insurers requiring patients to trial cheaper alternatives before reimbursement. Korsuva, one of the more promising pipeline assets, ran into reimbursement bundling in the United States that sharply curtailed its commercial potential.

The structural blow arrived in late 2025. Cheaper generic versions of Venofer launched in the US market. This was not a routine market‑share skirmish; it materially undermined the revenue assumptions embedded in the acquisition price. Generic entry in injectables is rarely reversed.

At the same time, CSL absorbed setbacks elsewhere. A self‑amplifying mRNA COVID‑19 vaccine developed with Arcturus was abandoned after it produced false‑positive HIV results, leading to a US$566m impairment. Several late‑stage R&D projects failed. Infrastructure was built ahead of demand. Invested capital grew faster than earnings. A higher cost of capital amplified every underperformance.

McKenzie departed abruptly in February 2026 after an internal review concluded he lacked the skills to take the company forward. Interim CEO Gordon Naylor launched a 90‑day review. The findings, delivered this week, were blunt and led to US$1.5bn in impairments booked in the first half of FY26 and a total of US$5bn for FY26/FY27 marking US$6.5bn all up.

Moreover, it slashed revenue guidance by US$600bn from US$15.8bn to US$15.2bn. The revised revenue figure would mark CSL’s first annual revenue decline in more than a decade. Shares fell roughly 17% on Monday May 11 to A$98.59, their lowest level since 2017. Year‑to‑date, the stock is down about 42%, following a 38.7% decline in 2025. The two‑year fall has erased decades of goodwill with institutional investors.

Naylor’s language was unusually candid. He spoke the truth, admitting that the Vifor acquisition was among “historical investment cases that did not eventuate” and pointed to failed R&D projects, market‑share losses and capital allocation decisions as contributors to a “loss of confidence in growth prospects.”

For a company long regarded as one of the ASX’s most disciplined operators, this admission carries weight even if it is good that the company had stopped trying to deny it was a problem by selling investors some kind of ‘long term growth’ spin.

Is There Hope?

The case for cautious optimism rests on what CSL still owns beneath the Vifor wreckage.

CSL Behring’s core plasma and immunoglobulin franchise remains structurally sound. Privigen’s US market share has risen from 19% to 21% between 2023 and 2025; Hizentra has moved from 55% to 57% over the same period. End‑customer demand for US immunoglobulins continues to grow at mid‑to‑high single‑digit rates.

In March 2026, CSL broke ground on a US$1.5bn expansion of its facility in southern Illinois (60 miles south of downtown Chicago), deploying its Horizon 2 fractionation technology to increase protein yield. This is not the behaviour of a company retreating from its core.

Management has also outlined a transformation program targeting A$500–550m in annual cost savings. An on‑market buyback is active. The balance‑sheet target of 1.5–2.0 times net debt to EBITDA signals a more disciplined capital‑allocation framework than the one that approved a 60% premium for Vifor.

The impairments, while substantial, are non‑cash. The core business continues to generate revenue. And the share price, around A$98, implies a level of pessimism not seen since 2017.

The key risk is that the write‑downs are not yet final. Management has flagged that the US$5bn figure remains subject to audit and board approval, with the next update due at the full‑year result on 18 August 2026. A second guidance cut cannot be ruled out. The ongoing CEO search adds execution uncertainty at a moment when the company needs stability.

Conclusion

In our view, the Vifor acquisition will be studied in top business schools as a case in the dangers of overpaying for diversification at the peak of a market cycle. CSL entered nephrology and iron deficiency from a position of strength but paid a price that left almost no room for the ordinary frictions of drug commercialisation, let alone generic entry and pipeline failure. The board’s concession this week is at least honest; the question is whether honesty alone can rebuild confidence.

The restoration of CSL as a quality compounder depends on two things: a permanent CEO with the operational credibility to execute the Behring recovery, and evidence at the August result that the impairment figure is final. Until both conditions are met, the stock remains a story about stabilisation rather than growth.